Showing results (481-490 of 489) with videos related to
Sort By:
Pageof 49
You have reached the last page of results.This site can display upto 489 results.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.Ocular Immunology and Inflammation|February 12, 2025
Incidence and Outcome of Cataract in Eyes with Scleritis and EpiscleritisMichelle J Sun, Bernard A Rosner, Craig W Newcomb, et al.Hepatology (Baltimore, Md.)|March 3, 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled TrialKeyur Patel, Stephen A Harrison, Magdy Elkhashab, et al.Ocular Immunology and Inflammation|February 5, 2025
Incidence and Outcomes of Cataract in Eyes with Ocular Cicatricial PemphigoidPichaporn Artornsombudh, Maxwell Pistilli, Craig W Newcomb, et al.Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.Archives of Dermatology|March 21, 2002
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicatorsLawrence S Chan, A Razzaque Ahmed, Grant J Anhalt, et al.Cornea|November 15, 2017
Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic PossibilitiesClaes H Dohlman, Fabiano Cade, Caio V Regatieri, et al.Ocular Immunology and Inflammation|April 15, 2025
Effectiveness of Frequently Used TNF Inhibitors vs. Conventional Immunosuppressive Therapies for Noninfectious UveitisSapna S Gangaputra, Craig W Newcomb, Gui-Shuang Ying, et al.Ophthalmology|July 27, 2023
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer MortalityJohn H Kempen, Craig W Newcomb, Terri L Washington, et al.Pageof 49